Stockholders' equity |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Stockholders' equity | |
| Stockholders' equity |
Note 13 — Stockholders’ equity On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of June 30, 2022, $197,360,000 remained available for sale under the Sales Agreement. On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the second quarter of 2022, the Company sold 5,927,662 ADSs under the agreement representing 35,565,972 ordinary shares (including 71,965 ADSs sold on June 30, 2022 representing 431,790 ordinary shares issued on July 5, 2022) resulting in net proceeds to the Company of $10,029,000 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of June 30, 2022, approximately $189,673,500 remained available for sale under the 2022 Sales Agreement. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|